Swiss pharma giant Novartis AG (NVS) reported lower-than-expected results in the fourth quarter of 2023. Core earnings (excluding one-time charges) of $1.53 per share missed the Zacks Consensus Estimate of$1.64. Higher expenses pulled down the bottom line. The figure was, nevertheless, up from $1.39 recorded a year ago. Revenues of$11.4 billion climbed 8% from the year-ago quarter's level. On a constant currency basis, sales increased 10%, driven by momentum in Entresto, Kesimpta, Kisqali, Cosentyx and Pl ...